Since the mid-point of this year investors have cooled on biotech equities with the BioWorld Biopharmaceutical Index slipping 4 percent in value over this period. It was a different story for the first six months, with the index growing a healthy 14 percent. This dramatic swing in sentiment took its toll on stock valuations with 44 percent of the biopharmas companies registering a drop in their share price over the year.